Brief: Globus Medical Q2 Adjusted EPS USD 0.86 Vs. IBES Estimate USD 0.76

Globus Medical

07/08/2025 21:15

Overview

Globus Medical Q2 sales rise 18.4%, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 beats estimates, reaching $0.86, per LSEG data

Growth driven by US Spine business and Nevro acquisition integration

Outlook

Company reaffirms 2025 revenue guidance of $2.80 bln  to $2.90 bln

Globus Medical maintains 2025 EPS guidance of $3.00 to $3.30

Result Drivers

US SPINE BUSINESS - US Spine segment grew 5.7% as reported, 7.4% on a day-adjusted basis, per CEO Keith Pfeil

ENABLING TECHNOLOGIES - Segment showed modest recovery in Q2, with focus on robotic assisted surgery

NEVRO ACQUISITION - Integration of Nevro acquisition contributed to sales growth, per CFO Kyle Kline

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$745.30 mln
$741.80 mln (12 Analysts)
Q2 Adjusted EPS
Beat
$0.86
$0.76 (14 Analysts)
Q2 EPS
$1.49
Q2 Net Income
$202.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Globus Medical Inc is $80.00, about 34% above its August 6 closing price of $52.83

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nGNX7GFmqw

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)